Preferred Name | rofecoxib | |
Synonyms |
Vioxx MK 966 4-[4'-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone |
|
Definitions |
A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties. Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins. COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1832" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1832" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000038568 |
|
altLabel |
Vioxx MK 966 4-[4'-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone |
|
CAS Registry |
162011-90-7 |
|
cui |
C0762662 C0876768 C0766718 |
|
Date last modified |
2006-05-10 |
|
definition |
A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties. Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins. COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1832" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1832" NCI Thesaurus) |
|
Legacy PDQ ID |
11199 |
|
LT |
TRD |
|
NCI ID |
C1832 |
|
notation |
CDR0000038568 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
rofecoxib |
|
tui |
T109 T121 |